GBA
ACAD icon

Garrison Bradford & Associates’s Acadia Pharmaceuticals ACAD Stock Holding History

Garrison Bradford & Associates’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-8,800
Closed -$227K – 53
2021
Q1 		$227K Hold
8,800
– – 0.25% 46
2020
Q4 		$470K Buy
8,800
+2,979
+51% +$148K 0.57% 33
2020
Q3 		$240K Sell
5,821
-100
-2% -$4.32K 0.34% 41
2020
Q2 		$287K Hold
5,921
– – 0.42% 35
2020
Q1 		$250K Sell
5,921
-600
-9% -$24.7K 0.43% 34
2019
Q4 		$279K Buy
6,521
+621
+11% +$27K 0.35% 39
2019
Q3 		$212K Sell
5,900
-22,800
-79% -$691K 0.29% 46
2019
Q2 		$767K Sell
28,700
-3,000
-9% -$76.6K 0.9% 27
2019
Q1 		$851K Sell
31,700
-1,000
-3% -$23.4K 0.72% 30
2018
Q4 		$529K Sell
32,700
-15,800
-33% -$307K 0.48% 37
2018
Q3 		$1.01M Sell
48,500
-5,000
-9% -$78.7K 0.81% 23
2018
Q2 		$817K Sell
53,500
-15,500
-22% -$276K 0.67% 27
2018
Q1 		$1.55M Sell
69,000
-5,150
-7% -$143K 1.32% 17
2017
Q4 		$2.23M Buy
74,150
+800
+1% +$25.6K 1.85% 14
2017
Q3 		$2.76M Sell
73,350
-500
-0.7% -$16.3K 2.31% 12
2017
Q2 		$2.06M Buy
73,850
+1,300
+2% +$38.7K 1.78% 14
2017
Q1 		$2.49M Hold
72,550
– – 2.2% 13
2016
Q4 		$2.09M Buy
72,550
+3,000
+4% +$79.4K 1.93% 15
2016
Q3 		$2.21M Sell
69,550
-550
-0.8% -$18.6K 2.08% 14
2016
Q2 		$2.27M Sell
70,100
-3,700
-5% -$124K 2.23% 13
2016
Q1 		$2.06M Buy
73,800
+11,400
+18% +$249K 2.4% 14
2015
Q4 		$2.23M Buy
62,400
+14,850
+31% +$523K 2.49% 12
2015
Q3 		$1.57M Buy
47,550
+7,450
+19% +$310K 1.74% 16
2015
Q2 		$1.68M Buy
40,100
+20,000
+100% +$774K 1.64% 18
2015
Q1 		$655K Buy
20,100
+8,350
+71% +$287K 0.61% 38
2014
Q4 		$373K Sell
11,750
-2,500
-18% -$70.9K 0.34% 64
2014
Q3 		$353K Sell
14,250
-200
-1% -$4.68K 0.35% 63
2014
Q2 		$326K Buy
14,450
+2,400
+20% +$50.1K 0.3% 73
2014
Q1 		$293K Sell
12,050
-100
-0.8% -$2.53K 0.28% 74
2013
Q4 		$304K Buy
+12,150
New +$287K 0.29% 66

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return

Garrison Bradford & Associates's ACAD Position: Q2 2021 in Review

Garrison Bradford & Associates sold out of Acadia Pharmaceuticals (ACAD) in Q2 2021, closing a stake of 8,800 shares — an estimated $227K sold.

Garrison Bradford & Associates first reported a position in ACAD in Q4 2013 and held it in 30 quarters. The position peaked at $2.76M in Q3 2017. 245 funds tracked by Wall St. Rank hold ACAD as of Q2 2021.

  • Garrison Bradford & Associates reported no remaining Acadia Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
  • Garrison Bradford & Associates sold 8,800 Acadia Pharmaceuticals shares in Q2 2021, an estimated $227K.
  • Garrison Bradford & Associates first reported a position in Acadia Pharmaceuticals in Q4 2013 and held it in 30 quarters.
  • Garrison Bradford & Associates's Acadia Pharmaceuticals position peaked at $2.76M in Q3 2017.
  • 245 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2021.

Based on Garrison Bradford & Associates's 13F filing for Q2 2021, filed 9 Aug 2021.